Abstract
Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Current Medicinal Chemistry
Title: Exploring Old Drugs for the Treatment of Hematological Malignancies
Volume: 18 Issue: 10
Author(s): F. Gan, B. Cao, D. Wu, Z. Chen, T. Hou and X. Mao
Affiliation:
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Abstract: Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Gan F., Cao B., Wu D., Chen Z., Hou T. and Mao X., Exploring Old Drugs for the Treatment of Hematological Malignancies, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328427
DOI https://dx.doi.org/10.2174/092986711795328427 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrixmetalloproteinase Inhibitors: Promising Therapeutic Targets Against Cancer
Current Pharmaceutical Design Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
Current Radiopharmaceuticals Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Investigation of the Pharmacokinetics of the ABCG2 Transporter Inhibitor Ko134 in Mice by a Newly Developed and Validated HPLC Method
Current Pharmaceutical Analysis PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets The Leukocyte Common Antigen-Related Protein LAR: Candidate PTP for Inhibitory Targeting
Current Topics in Medicinal Chemistry Activation of Myosin Phosphatase by Epigallocatechin-Gallate Sensitizes THP-1 Leukemic Cells to Daunorubicin
Anti-Cancer Agents in Medicinal Chemistry Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets